Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05629962
Other study ID # AT-03A-017
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date November 25, 2022
Est. completion date May 31, 2024

Study information

Verified date April 2024
Source Atea Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 2295
Est. completion date May 31, 2024
Est. primary completion date April 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Positive SARS-CoV-2 test conducted = 5 days prior to randomization - Mild or moderate COVID-19 with symptom onset = 5 days before randomization and at least one COVID-19 related symptom present at time of screening - Subject must be high risk, defined below: 1. Age =70 years OR 2. Age =55 years with one of the following: i) obesity (body mass index [BMI] =30 kg/m2) ii) diabetes mellitus iii) cardiovascular disease or hypertension iv) chronic lung disease requiring routine therapy OR 3. Age 50 to 54 years with two of the following: i) obesity (BMI =30 kg/m2) ii) diabetes mellitus iii) cardiovascular disease or hypertension iv) chronic lung disease requiring routine therapy OR 4. Age =18 years with one of the following: i) Down syndrome, sickle cell disease, dementia, Parkinson's disease, or care home residents ii) One of the following immunocompromising conditions or immunosuppressive treatments: receiving chemotherapy for cancer, hematologic malignancy, being within 2 years of a hematopoietic stem cell transplant, receipt of a solid organ transplant and on immunosuppressive therapy, human immunodeficiency virus (HIV) infection untreated or with CD4+ T lymphocyte count <350 cells per cubic millimeter, moderate/severe primary immunodeficiency, taking immunosuppressive medications - Use of adequate contraception for females of childbearing potential Exclusion Criteria: - Severe or critical COVID-19 illness - Admitted to a hospital within 90 days prior to randomization due to COVID-19 - Use of other investigational drugs within 30 days prior to planned dosing, or plans to enroll in another clinical trial of an investigational agent while participating in the present study - Initiation or planned initiation of remdesivir for treatment of the current SARS-CoV-2 infection - Requirement of prohibited medications, including hydroxychloroquine or amiodarone within 3 months prior to screening. Note: Subjects who had already initiated any COVID-19 drug with antiviral effects intended to treat symptomatic SARS-CoV-2 infection (= 24 hours prior to randomization) will be excluded. During screening (or within 24 hours prior to or after randomization), locally available COVID-19 drugs with antiviral effects (including but not limited to nirmatrelvir/ritonavir, molnupiravir, favipiravir, monoclonal antibodies) will be permitted. - Other known active viral or bacterial infection at the time of screening, such as influenza and respiratory syncytial virus (RSV). Note: This exclusion does not apply to subjects with stable chronic viral infections, such as chronic hepatitis C virus (HCV) or HIV providing other eligibility criteria are met. - Receiving dialysis or have known severe renal impairment - History of severe hepatic impairment (Child-Pugh Class C) - Known allergy or hypersensitivity to components of study drug

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bemnifosbuvir (BEM)
BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days
Placebo
Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days

Locations

Country Name City State
Argentina Atea Study Site Bahía Blanca Buenos Aires
Argentina Atea Study Site Buenos Aires Ciudad Autonoma Buenos Aires
Argentina Atea Study Site Ciudad Autonoma de Buenos Aire Buenos Aires
Argentina Atea Study Site Ciudad Autonoma de Buenos Aire
Argentina Atea Study Site Córdoba
Argentina Atea Study Site Córdoba Cordoba
Argentina Atea Study Site Mar Del Plata Buenos Aires
Argentina Atea Study Site Mar Del Plata Buenos Aires
Argentina Atea Study Site Ramos Mejía Buenos Aires
Argentina Atea Study Site Rosario Santa Fe
Argentina Atea Study Site Rosario Santa Fe
Argentina Atea Study Site San Miguel De Tucumán Tucuman
Argentina Atea Study Site San Miguel De Tucumán Tucuman
Argentina Atea Study Site San Nicolas Buenos Aires
Argentina Atea Study Site Santiago Del Estero
Brazil Atea Study Site Barretos Sao Paulo
Brazil Atea Study Site Belo Horizonte Minas Gerais
Brazil Atea Study Site Belo Horizonte Minas Gerais
Brazil Atea Study Site Belo Horizonte Minas Gerais
Brazil Atea Study Site Bento Gonçalves Sao Paulo
Brazil Atea Study Site Blumenau Santa Catarina
Brazil Atea Study Site Botucatu Sao Paulo
Brazil Atea Study Site Brasília Distrito Federal
Brazil Atea Study Site Cachoeiro De Itapemirim Espirito Santo
Brazil Atea Study Site Campina Grande Do Sul Parana
Brazil Atea Study Site Campinas Sao Paulo
Brazil Atea Study Site Cuiabá Mato Grosso
Brazil Atea Study Site Florianópolis Santa Catarina
Brazil Atea Study Site Fortaleza Ceara
Brazil Atea Study Site Fortaleza Ceara
Brazil Atea Study Site Ijuí Sao Paulo
Brazil Atea Study Site Itajaí Santa Catarina
Brazil Atea Study Site Itajaí Santa Catarina
Brazil Atea Study Site Jaú Sao Paulo
Brazil Atea Study Site Joinville Santa Catarina
Brazil Atea Study Site Maceió Alagoas
Brazil Atea Study Site Natal Rio Grande Do Norte
Brazil Atea Study Site Natal Rio Grande Do Norte
Brazil Atea Study Site Osasco Sao Paulo
Brazil Atea Study Site Passo Fundo Rio Grande Do Sul
Brazil Atea Study Site Porto Alegre Rio Grande Do Sul
Brazil Atea Study Site Porto Alegre Rio Grande Do Sul
Brazil Atea Study Site Porto Alegre Rio Grande Do Sul
Brazil Atea Study Site Porto Alegre Rio Grande Do Sul
Brazil Atea Study Site Porto Velho Rondonia
Brazil Atea Study Site Ribeirão Preto Sao Paulo
Brazil Atea Study Site Rio De Janeiro
Brazil Atea Study Site Rio De Janeiro Rio Do Janeiro
Brazil Atea Study Site Salvador Bahia
Brazil Atea Study Site Salvador Bahia
Brazil Atea Study Site Santa Catarina Sao Paulo
Brazil Atea Study Site São José Do Rio Preto Sao Paulo
Brazil Atea Study Site São Paulo Sao Paulo
Brazil Atea Study Site São Paulo Sao Paulo
Brazil Atea Study Site São Paulo Sao Paulo
Brazil Atea Study Site São Paulo Sao Paulo
Brazil Atea Study Site Serra Espirito Santo
Brazil Atea Study Site Valinhos São Paulo
Brazil Atea Study Site Vitória Espirito Santo
Canada Atea Study Site Chicoutimi Quebec
Canada Atea Study Site Edmonton Alberta
Germany Atea Study Site Berlin
Germany Atea Study Site Frankfurt am Main Hessen
Germany Atea Study Site Hamburg
Germany Atea Study Site Muenchen Bayern
India Atea Study Site Ahmedabad Gujarat
India Atea Study Site Bangalore Karnataka
India Atea Study Site Bangalore Karnataka
India Atea Study Site Bangalore Karnataka
India Atea Study Site Bengaluru Karnataka
India Atea Study Site Chennai Tamilnadu
India Atea Study Site Dombivli Maharashtra
India Atea Study Site Faridabad Haryana
India Atea Study Site Gotri Gujarat
India Atea Study Site Hyderabad Andhra Pradesh
India Atea Study Site Jaipur Rajasthan
India Atea Study Site Jaipur Rajasthan
India Atea Study Site Nashik Maharashtra
India Atea Study Site Nashik Maharashtra
India Atea Study Site Nellore Andhra Pradesh
India Atea Study Site Nellore Andhra Prasesh
India Atea Study Site New Delhi Delhi
India Atea Study Site Pune Maharashtra
India Atea Study Site Surat Gujarat
India Atea Study Site Surat Gujarat
India Atea Study Site Visakhapatnam Andhra Pradesh
Japan Atea Study Site Chiba
Japan Atea Study Site Fujisawa Kanagawa
Japan Atea Study Site Fukuoka
Japan Atea Study Site Fukuoka Fukuoka City
Japan Atea Study Site Fukuoka-Shi Fukuoka-Ken
Japan Atea Study Site Himeji Hyogo
Japan Atea Study Site Izumisano Osaka
Japan Atea Study Site Kamakura Kanagawa
Japan Atea Study Site Kanazawa Ishikawa
Japan Atea Study Site Kasuga Fukuoka
Japan Atea Study Site Kitakyushu Fukuoka-Ken
Japan Atea Study Site Okayama
Japan Atea Study Site Sapporo Hokkaido
Japan Atea Study Site Toda Saitama
Japan Atea Study Site Tsuchiura Ibaraki
Japan Atea Study Site Uozu Toyama
Latvia Atea Study Site Daugavpils
Latvia Atea Study Site Riga
Mexico Atea Study Site Cancún Quintana Roo
Mexico Atea Study Site Chihuahua
Mexico Atea Study Site Ciudad de mexico Mexico City
Mexico Atea Study Site Guadalajara Jalisco
Mexico Atea Study Site Mexico Distrito Federal
Mexico Atea Study Site Monterrey Nuevo Leon
Mexico Atea Study Site Monterrey Nuevo Leon
Mexico Atea Study Site Monterrey Nuevo Leon
Mexico Atea Study Site Monterrey Nuevo Leon
Mexico Atea Study Site Monterrey Nuevo Leon
Mexico Atea Study Site Oaxaca
Mexico Atea Study Site Puebla
Mexico Atea Study Site Querétaro Queretaro
Mexico Atea Study Site Saltillo Coahuila
Mexico Atea Study site San Luis Potosí San Luis Potos
Mexico Atea Study Site Torreon Coahuila
Mexico Atea Study Site Veracruz
Mexico Atea Study Site Veracruz
Mexico Atea Study Site Yucatán Yucatan
Netherlands Atea Study Site Den Haag
Netherlands Atea Study Site Den Haag
Netherlands Atea Study Site Utrecht
Netherlands Atea Study Site Zwijndrecht
Netherlands Atea Study Site Zwijndrecht
Pakistan Atea Study Site Islamabad
Pakistan Atea Study Site Karachi
Pakistan Atea Study Site Karachi
Pakistan Atea Study Site Lahore
Pakistan Atea Study Site Rawalpindi
Philippines Atea Study Site Baguio City Cordillera
Philippines Atea Study Site Ermita Manila
Philippines Atea Study Site Iloilo City
Philippines Atea Study Site Mandaluyong
Philippines Atea Study Site San Fernando Pampanga
Philippines Atea Study Site Tacloban City Leyte
Romania Atea Study Site Balotesti
Romania Atea Study Site Bucharest
Romania Atea Study Site Bucuresti
Romania Atea Study Site Bucuresti
Romania Atea Study Site Bucuresti
Romania Atea Study Site Constanta
Romania Atea Study Site Craiova
Romania Atea Study Site Oradea
Romania Atea Study Site Sibiu
Romania Atea Study Site Suceava
Romania Atea Study Site Timisoara
South Africa Atea Study Site Cape Town Western Cape
South Africa Atea Study Site East London Eastern Cape
South Africa Atea Study Site Johannesburg Gauteng
South Africa Atea Study Site Kimberley Northern Cape
South Africa Atea Study Site Plettenberg Bay Western Cape
South Africa Atea Study Site Pretoria Gauteng
South Africa Atea Study Site Pretoria Gauteng
South Africa Atea Study Site Pretoria Gauteng
South Africa Atea Study Site Randburg Gauteng
South Africa Atea Study Site Thabazimbi Limpopo
Spain Atea Study Site Badalona Barcelona
Spain Atea Study Site Barcelona
Spain Atea Study Site Centelles Barcelona
Spain Atea Study Site Madrid
Spain Atea Study Site Málaga Malaga
Spain Atea Study Site Marbella Malaga
Sweden Atea Study Site Solna
Sweden Atea Study Site Umeå
Tunisia Atea Study Site La Marsa
Tunisia Atea Study Site Monastir
Tunisia Atea Study Site Montfleury
Tunisia Atea Study Site Sfax
Tunisia Atea Study Site Sousse
Tunisia Atea Study Site Sousse
Tunisia Atea Study Site Tunis
Tunisia Atea Study Site Tunis
Turkey Atea Study Site Ankara
Turkey Atea Study Site Ankara
Turkey Atea Study Site Ankara
Turkey Atea Study Site Ankara
Turkey Atea Study Site Ankara
Turkey Atea Study Site Antalya
Turkey Atea Study Site Antalya
Turkey Atea Study Site Bursa
Turkey Atea Study SIte Denizli
Turkey Atea Study Site Istanbul
Turkey Atea Study Site Istanbul
Turkey Atea Study Site Istanbul
Turkey Atea Study Site Istanbul
Turkey Atea Study Site Istanbul
Turkey Atea Study Site Istanbul
Turkey Atea Study Site Izmir
Turkey Atea Study Site Izmir
Turkey Atea Study Site Izmir
Turkey Atea Study Site Izmir
Turkey Atea Study SIte Kayseri
Turkey Atea Study Site Samsun
Turkey Atea Study Site Yenimahalle
United Kingdom Atea Study Site Castleford West Yourkshire
United Kingdom Atea Study Site Exeter Devon
United Kingdom Atea Study Site London Greater London
United Kingdom Atea Study Site London Greater London
United Kingdom Atea Study Site Plymouth Devon
United States Atea Study Site Bronx New York
United States Atea Study Site Bronx New York
United States Atea Study Site Canoga Park California
United States Atea Study Site Carrollton Texas
United States Atea Study Site Chapel Hill North Carolina
United States Atea Study Site Chickasha Oklahoma
United States Atea Study Site Coral Gables Florida
United States Atea Study Site Cutler Bay Florida
United States Atea Study Site Dallas Texas
United States Atea Study Site DeSoto Texas
United States Atea Study Site Doral Florida
United States Atea Study Site Eatonton Georgia
United States Atea Study Site Forney Texas
United States Atea Study Site Fort Worth Texas
United States Atea Study Site Fullerton California
United States Atea Study Site Greenville South Carolina
United States Atea Study Site Harlingen Texas
United States Atea Study Site Hialeah Florida
United States Atea Study Site High Point North Carolina
United States Atea Study Site Houston Texas
United States Atea Study Site Inglewood California
United States Atea Study Site Kingman Arizona
United States Atea Study Site Kingwood Texas
United States Atea Study Site La Palma California
United States Atea Study Site La Vista Nebraska
United States Atea Study Site Lewisville Texas
United States Atea Study Site Long Beach California
United States Atea Study Site Long Beach California
United States Atea Study Site Los Angeles California
United States Atea Study Site Mesquite Texas
United States Atea Study Site Miami Florida
United States Atea Study Site Miami Florida
United States Atea Study Site Miami Florida
United States Atea Study Site Miami Florida
United States Atea Study Site Miami Florida
United States Atea Study Site Miami Florida
United States Atea Study Site Miami Florida
United States Atea Study Site Miami Gardens Florida
United States Atea Study Site North Miami Beach Florida
United States Atea Study Site North Miami Beach Florida
United States Atea Study Site Orland Park Illinois
United States Atea Study Site Pembroke Pines Florida
United States Atea Study Site Pompano Beach Florida
United States Atea Study Site Prescott Arizona
United States Atea Study Site Providence Rhode Island
United States Atea Study Site Rock Hill South Carolina
United States Atea Study Site Sacramento California
United States Atea Study Site San Antonio Texas
United States Atea Study Site San Diego California
United States Atea Study Site Splendora Texas
United States Atea Study Site Stafford Texas
United States Atea Study Site Sugar Land Texas
United States Atea Study Site Surprise Arizona
United States Atea Study Site Tampa Florida
United States Atea Study Site Tampa Florida
United States Atea Study Site Tampa Florida
United States Atea Study Site Tampa Florida
United States Atea Study Site The Villages Florida
United States Atea Study Site Tucson Arizona
United States Atea Study Site W. Miami Florida
United States Atea Study Site West Palm Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
Atea Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Brazil,  Canada,  Germany,  India,  Japan,  Latvia,  Mexico,  Netherlands,  Pakistan,  Philippines,  Romania,  South Africa,  Spain,  Sweden,  Tunisia,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects hospitalized for any cause or died due to any cause Day 1 through Day 29
Secondary Proportion of subjects hospitalized due to COVID-19 or died due to any cause Day 1 through Day 29
Secondary Proportion of subjects who died due to any cause Day 1 through Day 29; Day 1 through Day 60
Secondary Proportion of subjects with COVID-19-related complications Day 1 through Day 29
Secondary Proportion of subjects with COVID-19-medically attended visits (hospitalization, emergency room (ER) visit, urgent care visit, physician's office visit, or telemedicine visit) or who died due to any cause Day 1 through Day 29; Day 1 through Day 60
Secondary Proportion of subjects with COVID-19 symptom relapse Day 1 through Day 29
Secondary Proportion of subjects with viral load rebound Day 1 through Day 29
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure